Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ishares Msci Thailand Etf — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Ishares Msci Thailand Etf trades at $72.37. The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | THD | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $339.75 | $75.05 |
52-Week Low | $241.71 | $53.63 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
THD trades at $72.33, down 0.25% on the day, with technical indicators showing a bullish trend from moving averages and neutral oscillators. The stock faces key support at $72 and resistance at $73. A dividend of $1.71 is scheduled for payment on June 18, 2026. Recent news highlights THD's strong performance as an ASEAN ETF, driven by exposure to Delta Electronics and AI hardware plays, though this concentration introduces vulnerability to profit-taking.
The outlook for THD is cautiously optimistic given its technical strength and thematic tailwinds from AI, but risks include over-reliance on single holdings and regional economic sensitivity. Investors should weigh the ETF's recent outperformance against potential volatility from geopolitical and monetary policy shifts affecting Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
